StreetAlpha.app
Home › Stocks › LEGN

Legend Biotech Corp (LEGN)

Healthcare
$15.25
▼ −5.28%
LAST CLOSE · NOV 20

Legend Biotech develops and sells cell therapies for cancer, led by CARVYKTI for multiple myeloma. It last closed at $15.25 on Nov 20, down 5.28% on the day. Over the last 12 months LEGN insiders bought $346K of stock on the open market and sold $567K, according to SEC Form 4 filings.

AI Auto Pilots
Is LEGN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold LEGN.

Key Stats

Last 12 months
Results
Revenue
$1.0B
+64.0% vs a year ago
Net income
−$296.8M
−28.8% margin
Free cash flow
−$128.8M
−12.5% margin
Operating margin
−13.3%
−$136.5M operating income
Balance sheet
Cash & equivalents
$901.9M
At Dec 31
Debt
$319.1M
At Dec 31
Shareholder equity
$1.0B
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $68.8M$68.8MFY2021FY2022: $50.3M$50.3MFY2022FY2023: $285.1M$285.1MFY2023FY2024: $627.3M$627.3MFY2024FY2025: $1.0B$1.0BFY2025

From LEGN's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 10). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on file yet
Reported EPS
—
Quarter ended Dec 2025
Year ago EPS
—
Same quarter last year
Revenue
$973.5M
+94.3% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Not enough quarters on file yet.
Revenue by quarter
Mar 2024: $15.5MMar '24Jun 2024: $93.3MJun '24Sep 2024: $17.4MSep '24Dec 2024: $501.1MDec '24Mar 2025: $9.4MMar '25Jun 2025: $35.3MJun '25Sep 2025: $10.5MSep '25Dec 2025: $973.5MDec '25Latest $973.5M
StreetAlpha's call on LEGNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on LEGN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on LEGN

Technical Analysis

LEGN · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 31% below its 20 day and 26% below its 50 day average. It is 45% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), oversold. The nearest support is the 52 week low at $15.14, and the nearest resistance the Pivot at $15.51.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 8.6%/day
Key levels
$37.5052 week high+145.9%
$22.17200 day average+45.4%
$20.55100 day average+34.8%
$19.9820 day average+31.0%
$19.92Swing high (Oct 15)+30.6%
$19.1750 day average+25.7%
$15.87Pivot R1+4.1%
$15.51Pivot+1.7%
$15.25Last close
$15.1452 week low−0.7%
$14.89Pivot S1−2.4%
Indicators
RSI (14)31.50Weak, oversold below 30Neutral
MACD-1.10Below its signal lineBearish
Stochastic3.7Near the bottom of its rangeOversold
ADX (14)24.2Weak trend
Williams %R-98.9Oversold below −80, overbought above −20Oversold
CCI (20)-127.9Oversold below −100, overbought above 100Oversold
Rate of change−34.8%Change over 10 sessionsBearish
ATR (14)$1.31Typical daily range, 8.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for LEGN

What happened before

See how LEGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow LEGN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How LEGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for LEGNHow many large options trades hit LEGN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

LEGN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲120 buying vs 101 selling
  • ▼Held by funds -1.2 pts
  • ▼Funds holding -23
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding198221−10.4%
In funds' top 101112−8.3%
Held by funds27.2%28.4%−1.2 pts
New / increased33 / 8757 / 61+1.7%
Reduced / sold out46 / 5577 / 27−2.9%
Put/call ratio2.301.00+130.3%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LEGN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

LEGN Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$346K2 buys · 2 insiders
Sold$567K5 sales · 4 insiders
Cluster buy: 2 insiders bought $346K between Nov 12 and Nov 17.
2026-03 sold $87K2026-06 sold $171K2026-09 sold $309K2026-11 bought $346KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 17Ingrid ZhangCEOBuy20,000$8.16$163K
Nov 13Peter SaloveyDirectorBuy20,000$9.16$183K
Sep 29Corazon (Corsee) D. SandersDirectorSale27,370$9.46$259K
Sep 21Carlos E SantosCFOSale5,430$9.14$50K
Jun 30Patrick John CaseyDirectorSale6,000$14.80$89K
Jun 25Ying HuangCEOSale5,566$14.78$82K
Every insider buy and sale for LEGN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See LEGN insider trades →

From SEC Form 4 filings by LEGN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LEGN is in one of them and how their past LEGN trades turned out.

LEGN in the AI portfolios
Loading…

LEGN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LEGN in an article yet. Here's the latest on the wider market.

LEGN in the news

About Legend Biotech

Legend Biotech is a biopharmaceutical company in Somerset, New Jersey, that discovers, develops, manufactures and commercializes cell therapies for cancer. Its main product, CARVYKTI, treats multiple myeloma, a blood cancer, and is made from each patient's own immune cells. The company develops this therapy with Janssen and has other cancer cell therapies in early development, including for lung, gastric and pancreatic cancer.

Headquarters
Somerset, NJ